See more : NextNav Inc. (NN) Income Statement Analysis – Financial Results
Complete financial analysis of Cytocom, Inc. (CBLI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cytocom, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Fawry For Banking Technology An (EGS745L1C014.CA) Income Statement Analysis – Financial Results
- Thirumalai Chemicals Limited (TIRUMALCHM.BO) Income Statement Analysis – Financial Results
- Fertoz Limited (FTZZF) Income Statement Analysis – Financial Results
- Otto Energy Limited (OTTEF) Income Statement Analysis – Financial Results
- United Van Der Horst Limited (UVDRHOR.BO) Income Statement Analysis – Financial Results
Cytocom, Inc. (CBLI)
About Cytocom, Inc.
Cleveland BioLabs, Inc. operates as a biopharmaceutical company, which engages in the research and development of drugs. The company is headquartered in Buffalo, New York and currently employs 15 full-time employees. The firm is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications. Its other products include CBLB612, Mobilan and CBL0137. CBLB612 is a compound based upon a natural activator of another tissue-specific component of the innate immune system, the toll-like receptor 2 (TLR2)/ toll-like receptor 6 (TLR6) heterodimeric receptor. Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. CBL0137 is a small molecule with a multi-targeted mechanism of action that may be useful for the treatment of various types of cancer.
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 262.94K | 1.11M | 1.14M | 1.95M | 3.52M | 2.71M | 3.70M | 8.49M | 3.57M | 8.79M | 15.33M | 14.35M | 4.71M | 2.02M | 1.71M | 1.14M | 636.34K | 75.00K |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 262.94K | 1.11M | 1.14M | 1.95M | 3.52M | 2.71M | 3.70M | 8.49M | 3.57M | 8.79M | 15.33M | 14.35M | 4.71M | 2.02M | 1.71M | 1.14M | 636.34K | 75.00K |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 691.07K | 1.66M | 3.62M | 5.05M | 6.50M | 7.14M | 9.65M | 19.53M | 22.50M | 22.79M | 16.14M | 14.33M | 13.16M | 17.43M | 6.99M | 2.64M | 2.89M | 0.00 |
| General & Administrative | 2.16M | 1.82M | 2.32M | 2.50M | 3.38M | 6.36M | 8.47M | 12.04M | 11.12M | 11.11M | 9.93M | 6.40M | 5.89M | 10.53M | 2.14M | 986.42K | 262.82K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 2.16M | 1.82M | 2.32M | 2.50M | 3.38M | 6.36M | 8.47M | 12.04M | 11.12M | 11.11M | 9.93M | 6.40M | 5.89M | 10.53M | 2.14M | 986.42K | 262.82K | 0.00 |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 2.85M | 3.47M | 5.94M | 7.55M | 9.87M | 13.50M | 18.12M | 31.56M | 33.62M | 33.90M | 26.07M | 20.73M | 19.05M | 27.96M | 9.13M | 3.63M | 3.16M | 0.00 |
| Cost & Expenses | 2.85M | 3.47M | 5.94M | 7.55M | 9.87M | 13.50M | 18.12M | 31.56M | 33.62M | 33.90M | 26.07M | 20.73M | 19.05M | 27.96M | 9.13M | 3.63M | 3.16M | 0.00 |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 99.49K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.96K | 0.00 | 0.00 | 11.20K | 17.99K | 0.00 | 0.00 |
| Depreciation & Amortization | 11.45K | 13.78K | 18.18K | 21.08K | 63.46K | 140.14K | 200.79K | 471.21K | 479.60K | 525.51K | 407.29K | 362.14K | 324.35K | 188.40K | 94.93K | 44.76K | 2.30K | -211.83K |
| EBITDA | -2.39M | -2.63M | -3.59M | -9.69M | -2.60M | -12.40M | 1.83M | -16.79M | -30.05B | -3.49M | 0.00 | -12.46M | -13.70M | 0.00 | -7.12M | -2.32M | -2.52M | -136.83K |
| EBITDA Ratio | -907.81% | -236.50% | -315.75% | -497.10% | -73.77% | -457.79% | 49.43% | -197.83% | -497.23% | -39.68% | -169.32% | -86.87% | -291.18% | -1,328.08% | -416.61% | -204.04% | -396.15% | -182.43% |
| Operating Income | -2.59M | -2.36M | -4.80M | -5.60M | -6.36M | -10.79M | -14.42M | -23.08M | -30.05M | -25.11M | -10.74M | -6.38M | -14.35M | -25.94M | -7.42M | -2.49M | -2.52M | 75.00K |
| Operating Income Ratio | -983.70% | -212.03% | -421.72% | -287.46% | -180.65% | -398.45% | -389.58% | -271.88% | -841.47% | -285.60% | -70.03% | -44.49% | -304.86% | -1,285.18% | -434.26% | -218.45% | -395.93% | 100.00% |
| Total Other Income/Expenses | 148.68K | -333.83K | 1.09M | -4.24M | 3.77M | -2.25M | 14.46M | 2.95M | 7.63M | 19.88M | -16.03M | -6.46M | 414.73K | -2.06M | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -2.44M | -2.69M | -3.71M | -9.84M | -2.59M | -13.04M | 35.37K | -20.13M | -22.41M | -5.23M | -26.77M | -12.85M | -13.93M | -28.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -927.15% | -242.02% | -325.73% | -505.18% | -73.61% | -481.68% | 0.96% | -237.15% | -627.74% | -59.49% | -174.61% | -89.55% | -296.04% | -1,387.14% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 148.68K | -333.83K | 1.09M | -4.24M | 3.77M | -2.15M | 14.46M | 2.95M | 7.63M | 19.88M | -16.03M | -6.46M | 414.73K | -2.06M | 11.20K | 17.99K | 0.00 | 211.83K |
| Net Income | -2.40M | -2.65M | -3.61M | -9.71M | -2.66M | -12.64M | 1.63M | -17.26M | -18.23M | -4.01M | -26.37M | -12.83M | -14.03M | -27.00M | -7.22M | -2.39M | -2.52M | -136.83K |
| Net Income Ratio | -912.16% | -237.73% | -317.34% | -498.19% | -75.57% | -466.64% | 44.01% | -203.38% | -510.66% | -45.66% | -171.97% | -89.41% | -298.07% | -1,337.42% | -422.82% | -209.55% | -396.51% | -182.43% |
| EPS | -0.19 | -0.23 | -0.32 | -0.87 | -0.24 | -1.79 | 0.60 | -7.67 | -9.75 | -2.47 | -20.14 | -15.64 | -20.79 | -44.66 | -16.22 | -7.64 | -10.93 | -0.01 |
| EPS Diluted | -0.19 | -0.23 | -0.32 | -0.87 | -0.24 | -1.79 | 0.60 | -7.67 | -9.75 | -2.47 | -20.14 | -15.64 | -20.79 | -44.66 | -16.22 | -7.64 | -10.93 | -0.01 |
| Weighted Avg Shares Out | 12.40M | 11.30M | 11.29M | 11.19M | 10.99M | 7.06M | 2.70M | 2.25M | 1.87M | 1.63M | 1.31M | 820.26K | 674.62K | 604.52K | 445.31K | 312.52K | 230.78K | 15.48M |
| Weighted Avg Shares Out (Dil) | 12.40M | 11.30M | 11.29M | 11.19M | 10.99M | 7.06M | 2.70M | 2.25M | 1.87M | 1.63M | 1.31M | 820.26K | 674.62K | 604.52K | 445.31K | 312.52K | 230.78K | 15.48M |
The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus
Biotech stocks see-sawed through the week ended Jan. 31 and ended the month lower overall. Big pharma earnings of the week were mostly disappointing. Pfizer Inc. (NYSE: PFE ) reported disappointing fourth-quarter ...
The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus
Biotech stocks see-sawed through the week ended Jan. 31 and ended the month lower overall. Big pharma earnings of the week were mostly disappointing. Pfizer …
The Daily Biotech Pulse: Acceleron's Positive Data Readout, Surface Oncology Gets Nod For Pushing 2 Antibodies Into Clinics
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 27) 10X Genomics Inc (NASDAQ: TXG ) Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN )(announced early termination...
Analysts' Downgrades for January, 28th (ABBV, ACHC, ALGN, AMAT, ARGKF, ARWR, ATRC, ATVI, BGNE, BPFH)
Analysts’ downgrades for Tuesday, January 28th: AbbVie (NYSE:ABBV) was downgraded by analysts at ValuEngine from a hold rating to a sell rating. Acadia Healthcare (NASDAQ:ACHC) was downgraded by analysts at ValuEngine from a sell rating to a strong sell rating....
The Daily Biotech Pulse: Akebia Sues CMS, Roche Raises Guidance Yet Again, Titan Medical Entangled In Credit Crunch
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 15) Celgene Corporation (NASDAQ: CELG ) Eagle Pharmaceuticals Inc (NASDAQ: EGRX ) Kodiak Sciences Inc...
Glancy Binkow & Goldberg LLP Announces Investigation of Cleveland BioLabs, Inc.
LOS ANGELES--(BUSINESS WIRE)--Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of investors of Cleveland BioLabs, Inc. (“Cleveland BioLabs” or the “Company”) (NASDAQ: CBLI) concerning possible violations of federal securities laws. The investigation is focused...
Investor Alert: Cleveland BioLabs, Inc. Investigation Announced by Holzer & Holzer, LLC
ATLANTA--(BUSINESS WIRE)--Holzer & Holzer, LLC is investigating whether Cleveland BioLabs, Inc. (“Cleveland BioLabs” or the “Company”) (NASDAQ: CBLI) and/or certain of its officers complied with the federal securities laws in connection with the Company’s public securities offering on January 14,...
Source: https://incomestatements.info
Category: Stock Reports